Literature DB >> 32452746

Implementation of Preoperative Screening Protocols in Otolaryngology During the COVID-19 Pandemic.

Matthew J Urban1, Tirth R Patel1, Richard Raad1, Phillip LoSavio1, Kerstin Stenson1, Samer Al-Khudari1, Thomas Nielsen1, Inna Husain1, Ryan Smith1, Peter C Revenaugh1, R Mark Wiet1, Peter Papagiannopoulos1, Pete S Batra1, Bobby A Tajudeen1.   

Abstract

OBJECTIVE: To highlight emerging preoperative screening protocols and document workflow challenges and successes during the early weeks of the COVID-19 pandemic.
METHODS: This retrospective cohort study was conducted at a large urban tertiary care medical center. Thirty-two patients undergoing operative procedures during the COVID-19 pandemic were placed into 2 preoperative screening protocols. Early in the pandemic a "high-risk case protocol" was utilized to maximize available resources. As information and technology evolved, a "universal point-of-care protocol" was implemented.
RESULTS: Of 32 patients, 25 were screened prior to surgery. Three (12%) tested positive for COVID-19. In all 3 cases, the procedure was delayed, and patients were admitted for treatment or discharged under home quarantine. During this period, 86% of operative procedures were indicated for treatment of oncologic disease. There was no significant delay in arrival to the operating room for patients undergoing point-of-care screening immediately prior to their procedure (P = .92). DISCUSSION: Currently, few studies address preoperative screening for COVID-19. A substantial proportion of individuals in this cohort tested positive, and both protocols identified positive cases. The major strengths of the point-of-care protocol are ease of administration, avoiding subsequent exposures after testing, and relieving strain on "COVID-19 clinics" or other community testing facilities. IMPLICATIONS FOR PRACTICE: Preoperative screening is a critical aspect of safe surgical practice in the midst of the widespread pandemic. Rapid implementation of universal point-of-care screening is possible without major workflow adjustments or operative delays.

Entities:  

Keywords:  COVID-19; PS/QI; coronavirus; operating room; otolaryngology; preoperative; protocol; screening; surgery

Mesh:

Year:  2020        PMID: 32452746     DOI: 10.1177/0194599820931041

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  5 in total

1.  Meta-analysis of COVID-19 prevalence during preoperative COVID-19 screening in asymptomatic patients.

Authors:  Ellen de Bock; Mando D Filipe; Roger K J Simmermacher; A Christiaan Kroese; Menno R Vriens; Milan C Richir
Journal:  BMJ Open       Date:  2022-07-07       Impact factor: 3.006

2.  Prevalence of SARS-CoV-2 infection in asymptomatic preoperative patients scheduled for dermatologic surgery: A single-center retrospective chart review.

Authors:  Selcen S Yuksel; Alvin W Li; Simon S Yoo
Journal:  J Am Acad Dermatol       Date:  2022-05-16       Impact factor: 15.487

3.  Evaluating the Efficacy of a Screening Protocol for Severe Acute Respiratory Syndrome Coronavirus 2 Virus in Asymptomatic Preoperative/Preprocedural Patients at a Military Hospital.

Authors:  Cooper Barber; Andrew Syski; Jennifer Leaird; R Christopher Call; Ann Williams; Peter Learn
Journal:  Mil Med       Date:  2021-12-11       Impact factor: 1.563

4.  Postoperative nosocomial COVID-19 infection in surgical patients during pandemic: A prospective observational cohort study.

Authors:  Narjes Mohammadzadeh; Alireza Abkhoo; Mohammad Ashouri; Amirmohsen Jalaeefar; Amirmasoud Kazemzadeh Houjaghan; Behnam Ghorbani; Sara Ataie-Ashtiani; Mohammadreza Salehi; Ali Jafarian
Journal:  Ann Med Surg (Lond)       Date:  2022-09-30

5.  Risk of Acquiring Perioperative COVID-19 During the Initial Pandemic Peak: A Retrospective Cohort Study.

Authors:  Lucas G Axiotakis; Brett E Youngerman; Randy K Casals; Tyler S Cooke; Graham M Winston; Cory L Chang; Deborah M Boyett; Anil K Lalwani; Guy M McKhann
Journal:  Ann Surg       Date:  2021-01-01       Impact factor: 13.787

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.